HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Goldenberg, D. M.

CA: A Cancer Journal for Clinicians, Vol 44, Issue 1 43-64, Copyright © 1994 by American Cancer Society

ARTICLES

New developments in monoclonal antibodies for cancer detection and therapy

D. M. Goldenberg
Center for Molecular Medicine and Immunology, Newark, New Jersey.

Monoclonal antibodies have provided clinicians with an intriguing, target-specific approach to cancer management. Used alone or conjugated with drugs, toxins, or radionuclides, monoclonal antibodies have been shown to be useful in the detection and/or treatment of several cancers. Recent advances, such as the development of "humanized" antibodies, promise to increase their effectiveness even more. This article summarizes the status of the in vivo use of monoclonal antibodies for cancer detection and therapy.

This article has been cited by other articles:

				J. M. Tuscano, R. T. O'Donnell, L. A. Miers, L. A. Kroger, D. L. Kukis, K. R. Lamborn, T. F. Tedder, and G. L. DeNardo Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts Blood, May 1, 2003; 101(9): 3641 - 3647. [Abstract] [Full Text] [PDF]